# Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity

- Link: https://www.thailand-business-news.com/pr-news/ascletis-announces-u-s-fda-ind-clearance-for-phase-i-study-of-once-monthly-subcutaneously-administered-glp-1r-gipr-dual-peptide-agonist-asc35-for-the-treatment-of-obesity
- Published: 2026-06-23T17:10:00+07:00
- Author: PR Newswire

|   |

 ◦ _Phase I trial consists of two parts. Part A is a single ascending dose (SAD)
   study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part
   B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly
   SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized
   tirzepatide once-weekly formulation._
 ◦ _In head-to-head non-human primate (NHP) studies, the average observed half-life
   of ASC35 was approximately six-fold longer than tirzepatide, which supports once-
   monthly subcutaneous (SQ) dosing in humans. _
 ◦ _In a head-to-head diet-induced obese (DIO) mouse study, ASC35 demonstrated approximately
   71% greater relative body weight reduction compared to tirzepatide._

HONG KONG, June 23, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis")
announces today that it recently received Investigational New Drug (IND) clearance
from the U.S. Food and Drug Administration (FDA) for the Phase I study of ASC35,
a potentially best-in-class, once-monthly subcutaneously administered GLP-1 receptor(
GLP-1R)/GIP receptor (GIPR) dual peptide agonist, for the treatment of obesity.

The Phase I trial is a randomized, double-blind, placebo-controlled clinical trial
designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics
of ASC35 following single and multiple ascending doses in 84 participants with obesity(
body mass index (BMI) ≥30.0 kg/m²) or overweight (BMI ≥27.0 kg/m²) with weight-related
comorbidities. The Phase I trial consists of two parts. Part A is a single ascending
dose  (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation;
Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly
SALD formulation compared to the U.S. FDA-approved tirzepatide once-weekly formulation.

ASC35 was discovered and developed in-house utilizing Ascletis’ Artificial Intelligence-
Assisted Structure-Based Drug Discovery (AISBDD) technology.  ASC35 once-monthly
SALD formulation was developed utilizing Ascletis’ Ultra-Long-Acting Platform (ULAP)
technology.

SALD formulation is a low-viscosity solution which is composed of lipids, biocompatible
organic solvents, and the active pharmaceutical ingredient (API). The low-viscosity
solution can be easily administered into the subcutaneous tissue using an injection
pen/auto-injector with a fine needle as thin as 29 gauge. After subcutaneous (SQ)
administration, the solution transforms into a gel-like depot in the tissue. Under
the action of enzymes in the tissue, the depot slowly degrades, releasing the API
over a one-month or longer period.

In head-to-head non-human primate (NHP) studies, ASC35 SALD formulation with SQ 
administration exhibited an average observed half-life of approximately six-fold
longer than tirzepatide in its FDA-authorized SQ formulation. The longer observed
half-life and a flatter pharmacokinetic profile of ASC35 in NHPs compared to other
peptide incretins may also translate into a better gastrointestinal tolerability
in humans.  

In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ administration
were approximately 80% and 70% greater than tirzepatide I.V. and SQ administration,
respectively.

In a head-to-head diet-induced obese (DIO) mouse study, which is well established
as being highly predictive of human efficacy, dosed with equal molar concentrations
of ASC35 and tirzepatide, ASC35 demonstrated a relative greater efficacy of 71% 
compared to tirzepatide. 

ASC35 was approximately four-fold more potent than tirzepatide for both GLP-1R and
GIPR _in vitro_. Combination of all preclinical studies suggests ASC35 is more efficient
on a per-milligram peptide basis compared to tirzepatide.

"The FDA’s IND clearance for ASC35 once-monthly utilizing our proprietary SALD formulation
is an exciting and significant milestone for Ascletis’ peptide pipeline to treat
obesity as we advance multiple once-monthly to once-quarterly SQ administered peptides
into the clinic," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis,"
ASC35’s potential for superior weight loss combined with a more versatile and patient-
friendly once-monthly SQ injection will address a major unmet need in the rapidly
growing obesity market."

**About Ascletis Pharma Inc.**

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the 
development and commercialization of potential best-in-class and first-in-class 
therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-
assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (
ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT),
Ascletis has developed multiple drug candidates in-house, including both small molecules
and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed
to be administered once daily orally and once monthly to once quarterly subcutaneously
as a treatment therapy and a maintenance therapy for chronic weight management; 
ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously 
administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple
peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small
molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC)
of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis
is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit [www.ascletis.com](https://www.ascletis.com/).

Contact：
Peter VozzoICR Healthcare443-231-0505 (U.S.)[Peter.vozzo@icrhealthcare.com](https://www.thailand-business-news.com/pr-news/Peter.vozzo@icrhealthcare.com)

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)[pr@ascletis.com](https://www.thailand-business-news.com/pr-news/pr@ascletis.com)
[ir@ascletis.com](https://www.thailand-business-news.com/pr-news/ir@ascletis.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity ](http://www.prnasia.com/story/archive/4989883_AE89883_0?rand=184833)
